Answers are grounded in this paper and cite their sources.
As practice patterns and hepatitis C virus (HCV) genotypes (GT) vary geographically, a global real-world study from both East and West covering all GTs can help inform practice policy toward the 2030 HCV elimination goal. This study aimed to assess the effectiveness and tolerability of DAA treatment in routine clinical practice in a multinational cohort for patients infected with all HCV GTs, focusing on GT3 and GT6.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: